Description: Advanced Solid Tumors: ABBV-400 as Monotherapy-A Global First-in-Human Study Target Patient Population: All solid tumors Study Design: Study drug is administered IV every 3 weeks For more information on this trial, read its profile on clinicaltrials.gov here.
Clinical Trial Type: Solid Tumor
C-1400-01 (AGEN1777) (Agenus, Inc.)
C-1400-01 (AGEN1777) (Agenus, Inc.) Description: A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors Target Population: All solid tumors. To be given as single agent or in combination with Balstilimab Study Design: Study drug is administered IV every 3 weeks.
19951-CL-0101 (Astellas)
ALPN-202-NEON-2 (Alpine Immune Sciences)
BBI-20201001 (Bolt)
BBI-20201001 (Bolt) Description: Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors Target Patient Population: Advanced solid tumor patients with IHC 2+/3+/or Her2 amp on NGS/FISH/CISH. Study Design: Study Drug will be administered IV every 3 weeks.
CA115-001 (Bristol Myers Squibb)
CA115-001 (Bristol Myers Squibb) Description: Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small cell Lung Cancer Target Patient Population: Starting with dose escalation in advanced solid tumors with specific cohorts in combination with Nivolumab Study Design: Study Drug will be administered IV
CPI-0209-01 (Constellation)
CPI-0209-01 (Constellation) Description: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors Target Patient Population: In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial. Study Design: Drug is given orally daily.
CLN-619-001 (Cullinan)
CLN-619-001 (Cullinan) Description: A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Target Patient Population: All solid tumors. Monotherapy arms and combination arms administered with Pembrolizumab Study Design: Drug is administered IV weekly in
Debio 0123-102 (Debiopharm)
Debio 0123-102 (Debiopharm) Description: A Phase 1, Dose Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity Target Patient Population: All solid tumors in Dose Escalation Study Design: Drug is given orally daily.